Relay Therapeutics Inc (RLAY)

May 29, 2025, 4:05 PM EDT - 2 days ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

May 8, 2025, 4:05 PM EDT - 23 days ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

May 5, 2025, 4:05 PM EDT - 26 days ago

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

Apr 28, 2025, 4:05 PM EDT - 4 weeks ago

Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

Apr 12, 2025, 9:28 AM EDT - 7 weeks ago

Relay Therapeutics: Trying To Find That Right Price

Feb 26, 2025, 4:05 PM EST - 3 months ago

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Feb 19, 2025, 4:05 PM EST - 3 months ago

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

Feb 14, 2025, 2:17 AM EST - 3 months ago

Relay Therapeutics: A Precision Oncology Play Worth The Risk

Jan 7, 2025, 4:05 PM EST - 5 months ago

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 6:00 AM EST - 6 months ago

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

Dec 9, 2024, 4:05 PM EST - 6 months ago

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

Dec 3, 2024, 8:01 AM EST - 6 months ago

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Dec 3, 2024, 8:00 AM EST - 6 months ago

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Nov 6, 2024, 4:05 PM EST - 7 months ago

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 30, 2024, 4:05 PM EDT - 7 months ago

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

Sep 16, 2024, 4:57 PM EDT - 9 months ago

Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion

Sep 11, 2024, 8:15 AM EDT - 9 months ago

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Sep 11, 2024, 8:06 AM EDT - 9 months ago

GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

GME WOOF

Sep 10, 2024, 8:21 PM EDT - 9 months ago

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

Sep 10, 2024, 2:50 PM EDT - 9 months ago

Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market

Sep 10, 2024, 10:03 AM EDT - 9 months ago

This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

JCI DK EQR ORCL

Sep 9, 2024, 4:34 PM EDT - 9 months ago

Relay Therapeutics Announces Proposed Public Offering of Common Stock

Sep 9, 2024, 2:16 PM EDT - 9 months ago

Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher

Sep 9, 2024, 11:30 AM EDT - 9 months ago

Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients

Sep 9, 2024, 7:04 AM EDT - 9 months ago

Relay Therapeutics' combo therapy for breast cancer cuts disease progression in early study

Sep 9, 2024, 6:55 AM EDT - 9 months ago

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

Sep 6, 2024, 4:05 PM EDT - 9 months ago

Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024

Aug 6, 2024, 4:05 PM EDT - 10 months ago

Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Relay Therapeutics Discloses Three New Programs at New Program & Platform Event

Jun 5, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608

May 21, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics to Participate in Upcoming Investor Conferences

May 13, 2024, 8:30 AM EDT - 1 year ago

Relay Therapeutics to Host New Program and Platform Event on June 6, 2024

May 2, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024

Feb 26, 2024, 4:05 PM EST - 1 year ago

Relay Therapeutics to Participate in Three Upcoming Investor Conferences

Feb 22, 2024, 4:05 PM EST - 1 year ago

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Feb 15, 2024, 4:05 PM EST - 1 year ago

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024

Feb 1, 2024, 4:05 PM EST - 1 year ago

Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 8, 2024, 7:00 AM EST - 1 year ago

Relay Therapeutics Announces $30 Million Private Placement Financing

Jan 2, 2024, 4:05 PM EST - 1 year ago

Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Nov 7, 2023, 4:05 PM EST - 1 year ago

Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference

Nov 6, 2023, 2:05 AM EST - 1 year ago

Relay Therapeutics: Market Is Underestimating Lirafugratinib's Potential (Rating Upgrade)

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights

Oct 12, 2023, 4:05 PM EDT - 1 year ago

Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors

Sep 18, 2023, 4:05 PM EDT - 1 year ago

Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aug 8, 2023, 4:02 PM EDT - 1 year ago

Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 1, 2023, 4:05 PM EDT - 1 year ago

Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023

Jul 28, 2023, 6:04 AM EDT - 2 years ago

Relay Therapeutics: Market May Be Prematurely Dismissing RLY-2608

May 25, 2023, 5:01 PM EDT - 2 years ago

Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008

May 4, 2023, 4:05 PM EDT - 2 years ago

Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights